← Back to Calendar

GSBR-1290

Structure Therapeutics · $GPCR

Standard Review Phase 2

PDUFA Date

May 1, 2026

Time Remaining

38 days

Review Type

Standard (10 mo)

Indication

Obesity / overweight (oral GLP-1 receptor agonist)

Key Notes

Phase 2b ACHIEVE trial data expected H1 2026. GSBR-1290 is a novel oral non-peptide GLP-1 agonist — potential oral competitor in the obesity market alongside Lilly's orforglipron.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar